Company: TELO
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021496
Chunk: 47

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 8
Chunk 47
---
    $5.02  
     9.6  
    $- 
  
    Options granted 
     2,050,000  
    $2.12  
              -  
    $      - 
  
    Expired 
     (62,500) 
    $5.02  
     -  
    $- 
  
    Forfeitures 
     (150,000) 
    $5.02  
     -  
    $- 
  
    Outstanding as September 30, 2025 
     4,190,170  
    $3.60  
     9.2  
    $- 
  
    Exercisable 
     4,120,170  
    $3.60  
     9.2  
    $- 

On
May 13, 2025, the Company’s CFO was granted 50,000 options to purchase Common Stock with an aggregate fair market value of approximately
$0.1 million. The options have a term of 10 years from the grant date. These options vest as follows: 50% vest on the 6-month anniversary
of the date of grant and the remaining 50% vest on the 12-month anniversary of the date of grant.

On
May 27, 2025, the Company’s CEO was granted 2,000,000 options to purchase Common Stock with an aggregate fair market value of approximately
$3.7 million. The options have a term of 10 years from the grant date and were all vested as of the grant date.

The
fair value of the options granted in 2025 were estimated on the grant date using the Black-Sholes valuation method and level 3 inputs
based on assumptions for expected volatility, expected dividends, expected term and the risk-free interest rate which resulted in $3.8
million in option valuation during the nine months ended September 30, 2025.

Key
assumptions used to value warrants issued in the quarter are as follows:

Schedule
of key assumptions used to value warrants issued 

    Expected price volatility range 
     92.45%-138.97% 

    Risk-free interest rate range 
     4.08%-4.15% 

    Fair Market Value of Underlying Common Stock range 
     $1.87-$2.06 

    Expected Term in